Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 40 years or more~* Patients at risk of venous thromboembolic events being hospitalized for acute medical conditions as follows:~  * Heart failure, New York Heart Association (NYHA) class III or IV~ * Active cancer~ * Acute ischemic stroke~ * Acute infectious and inflammatory diseases, including acute rheumatic diseases~ * Acute respiratory insufficiency~ * Additional risk factor for VTE, including reduced mobility~Exclusion Criteria:~* Conditions that contraindicate the use of antithrombotic therapy with the Low Molecular-Weight Heparin (LMWH) enoxaparin~* Conditions that may increase the risk of bleeding, including intracranial hemorrhage~* Required drugs or procedures which may interfere with the study treatment~* Concomitant conditions or diseases which may increase the risk of study subjects or interfere with the study outcome~* General conditions in which subjects are not suitable to participate in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
- Enoxaparin (Type: ACTIVE_COMPARATOR): Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).